CLINICAL_TRIALS trial_result · 2017-06-23

Clinical Trial Update: Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma [Phase 2]

Phase 2 study of NY-ESO-1 ISCOMATRIX in patients with measurable Stage III/IV melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Ludwig Institute for Cancer Research | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2017-06-23